Nanohale AG (FYB) | Finanzwire

Basculer en Français

8302	Companies
115108	Keywords
55442	Articles
62528	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 06/13/2024 at 15:35, 5 months 8 days ago

Formycon Announces AGM Results and Board Changes

Shareholders 2023 Financial Year Supervisory Board AGM Formycon
PRESS RELEASE

published on 06/13/2024 at 15:30, 5 months 8 days ago

Formycon reports on the results of the Annual General Meeting
Formycon AG reports on the results of its Annual General Meeting, including approvals of agenda items, new Supervisory Board members, and election of new Chairman

Annual General Meeting Shareholders Supervisory Board Formycon AG Biosimilars
BRIEF

published on 06/13/2024 at 10:46, 5 months 8 days ago

First Berlin Equity Research Lowers Price Target for Formycon AG to €80

First Berlin Equity Research Buy Recommendation Formycon AG FYB202 Stelara
PRESS RELEASE

published on 06/13/2024 at 10:41, 5 months 8 days ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH reaffirms Buy recommendation for Formycon AG and lowers price target to €80 amid expected launch of lucrative biosimilar FYB202. Analyst Simon Scholes provides insights on Formycon's future prospects and market dynamics

Stock Market Analysis Buy Recommendation Formycon AG First Berlin Equity Research GmbH Biosimilar
BRIEF

published on 06/13/2024 at 07:36, 5 months 8 days ago

Formycon Starts Clinical Development for FYB206, a Keytruda Biosimilar

Clinical Trials Biosimilars Formycon FYB206 Keytruda
PRESS RELEASE

published on 06/13/2024 at 07:31, 5 months 8 days ago

Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
Formycon initiates clinical program for FYB206, a biosimilar candidate for Keytruda, targeting immuno-oncology. Phase I and III trials underway to assess safety, efficacy, and PK equivalence

Clinical Development Biosimilar Formycon FYB206 Keytruda
BRIEF

published on 05/15/2024 at 07:35, 6 months 6 days ago

MS Pharma Partners with Formycon for Commercialization of FYB203 in MENA

MENA Region MS Pharma Biosimilar Formycon FYB203
PRESS RELEASE

published on 05/15/2024 at 07:30, 6 months 6 days ago

MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
Formycon AG partners with MS Pharma for commercializing FYB203, a biosimilar candidate to Eylea in the MENA region, strengthening biosimilar portfolio and local production

Formycon AG MS Pharma Biosimilar FYB203 Eylea
BRIEF

published on 05/08/2024 at 07:35, 6 months 13 days ago

Formycon Reports Steady Performance in Q1 2024 Despite Challenges

Formycon AG Q1 2024 Financial Results Biosimilars Development Gedeon Richter Partnership Biopharmaceutical Market
PRESS RELEASE

published on 05/08/2024 at 07:30, 6 months 13 days ago

Formycon reports on successful operating business and financial figures for the first quarter of 2024
Formycon reports successful Q1 2024 operating business and financial figures, including acquisitions and strategic investments. Revenue at €17.7 million. Invitation to conference call

Acquisitions Financial Figures Strategic Investments Q1 2024 Formycon

Accesswire

Published on 11/21/2024 at 20:15, 1 hour 20 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 1 hour 25 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 1 hour 35 minutes ago

Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt
Published on 11/21/2024 at 19:25, 2 hours 10 minutes ago

Ibero Mining Reports Results From Deep Undercut Drill Hole At Miguel Vacas Mine
Published on 11/21/2024 at 17:35, 4 hours ago

1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 19:01, 2 hours 34 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 2 hours 59 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 3 hours 36 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 3 hours 43 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 3 hours 43 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.

Les Echos

Published on 11/21/2024 at 06:58, 14 hours 37 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 2 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 3 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 3 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 13 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE